Clinical trials: Nevirapine
HIV Infections
An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.
To evaluate the potential pharmacokinetic interaction between nevirapine and clarithromycin, and to determine the effects of nevirapine on cytochrome P450 3A4 (CYP3A4) activity in vivo.
- Trial name
- NCT00002194
- Testing
- Erythromycin, Nevirapine, Clarithromycin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)
The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).
- Trial name
- NCT00552240
- Testing
- tenofovir DF 300 mg QD, emtricitabine 200 mg QD, Nevirapine 200 mg BID
- Where
- 19 sites in United States
- Volunteers
- 154 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Daily Nevirapine to Prevent Mother to Infant Transmission of HIV
Infants who are breast-fed by HIV infected mothers have an increased risk of becoming infected with HIV. Standard therapy for the prevention of HIV infections in infants included zidovudine (ZDV) prior to the onset of labor, a…
- Trial name
- SWEN (NCT00061321)
- Testing
- Nevirapine and mulitvitamins
- Where
- India
- Volunteers
- 770 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
VENICE Study Nevirapine Full Dose/Dose Escalation
This study aims to compare the trough plasma concentrations of nevirapine after 7 days of treatment at the full dose from baseline with dose escalation in patients taking efavirenz who switch to nevirapine due to neuropsychiatric…
- Trial name
- VENICE (NCT00704249)
- Testing
- nevirapine
- Where
- 15 sites in Spain
- Volunteers
- 80 people
- Sponsor
- Clinical Trial Agency of HIV Study Group
HIV Infections
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
This Post Marketing Surveillance study will be performed as an open-label, prospective, non-interventional, uncontrolled study in Human immunodeficit Virus-1 (HIV-1) infected patients.
- Trial name
- NCT01524900
- Where
- 53 sites in Austria, Poland and 1 more
- Volunteers
- 398 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women
The purpose of this study is to look at the level of depo-medroxyprogesterone acetate (DMPA or Depo-Provera) in the blood to see if is affected by certain anti-HIV drugs (nelfinavir [NFV], efavirenz [EFV], indinavir [IDV] in…
- Trial name
- NCT00016601
- Testing
- Indinavir sulfate, Ritonavir, Nelfinavir mesylate
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 76 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Quality of Life
Quality of Life and Changes in Metabolism of Lipids and Glucose After Switching to a Nevirapine-based Regimen in HIV+ Patients
The purpose of this trial is to compare the effect of switching to nevirapine (Viramune®)-containing regimen on quality of life of patients with fat abnormalities and virological control whilst receiving a PI-based regimen.
- Trial name
- NCT00274001
- Testing
- Nevirapine
- Where
- 24 sites in Italy
- Volunteers
- 158 people
- Sponsor
- Boehringer Ingelheim
HIV-infection, Pregnancy
The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance
The primary objective of this two-phase trial is as follows: To determine the elimination half-life of NVP in HIV positive pregnant women receiving it as a single dose in labour in addition to the ZDV and 3TC with or without…
- Conditions
- HIV-infection, Pregnancy, Mother to Child Transmission
- Trial name
- VITA 2 (NCT01187719)
- Testing
- phenytoin
- Where
- 2 sites in Tanzania, Zambia
- Volunteers
- 66 people
- Sponsor
- Radboud University Medical Center
Acquired Immunodeficiency Syndrome
A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)
To determine whether a regimen of single dose nevirapine combined with either 4 or 7 days of Combivir®, compared to a regimen of single dose nevirapine, for the prevention of mother to child transmission can reduce the rate of…
- Trial name
- NCT00144183
- Testing
- Nevirapine (NVP), Zidovudine (ZCV), 3TC
- Where
- 5 sites in South Africa
- Volunteers
- 407 people
- Sponsor
- Boehringer Ingelheim
HIV Infection, Antiretroviral Treatment
Nevirapine / Lamivudine for HIV Maintenance Therapy
The standard treatment for HIV infection involves taking a combination of three HIV drugs. The main reason for using multiple substances is to prevent resistance from developing rapidly when only one or two drugs are used.
- Conditions
- HIV Infection, Antiretroviral Treatment, Maintenance Therapy
- Trial name
- NCT07014189
- Testing
- Neviparine (NVP)/ Lamivudine (3TC)
- Where
- Switzerland
- Volunteers
- 201 people
- Sponsor
- Cantonal Hospital of St. Gallen
HIV Infections, Hepatic Insufficiency
A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions
The objective of this study was to evaluate the steady-state clearance of nevirapine among HIV-1 positive patients with hepatic fibrosis, and to examine whether the degree of hepatic impairment influences clearance.
- Trial name
- NCT00144248
- Testing
- nevirapine
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 51 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients
The purpose of this study is to examine how the level of HIV is reduced in the blood when anti-HIV therapy is initiated. This study will also evaluate whether adding GM-CSF or IL-12 to the anti-HIV drug regimen will increase the…
- Trial name
- NCT00000896
- Testing
- Indinavir sulfate, Lamivudine/Zidovudine, Hepatitis A Vaccine (Inactivated)
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Case-Control Viramune (Nevirapine) Toxicogenomics Study
Attempt to identify genetic polymorphisms in interrogated pathways which may be associated with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within the first 8 weeks of nevirapine therapy.
- Trial name
- NCT00310843
- Testing
- Nevirapine
- Where
- 102 sites in United States, Argentina and 9 more
- Volunteers
- 889 people
- Sponsor
- Boehringer Ingelheim
Healthy
Pharmacokinetic Properties of Nevirapine Extended Release Tablets When Administered Orally in Healthy Male Volunteers
Study to determine the pharmacokinetic properties of 200 mg nevirapine (NVP) administered as 4 x 50 mg extended release (XR) tablets in a single dose and to establish the bioequivalence of this formulation compared to 200 mg NVP…
- Trial name
- NCT02194218
- Testing
- Nevirapine, low dose, Nevirapine, high dose
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV Infections
Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs
For PRAM-1: To evaluate zidovudine (ZDV) + lamivudine (3TC) vs. stavudine (d4T) + ritonavir vs. ZDV + 3TC + ritonavir with respect to the change in plasma HIV-1 RNA copy number from baseline to 48 weeks [AS PER AMENDMENT 1/5/98…
- Trial name
- NCT00001083
- Testing
- Indinavir sulfate, Ritonavir, Nevirapine
- Where
- 61 sites in United States, Puerto Rico
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Drug Resistance
An Evaluation of the Development of Nevirapine Induced Mutations in HIV Patients Initiating or Discontinuing Combination Antiretroviral Therapy
Hypothesis Nevirapine resistance developed in women and infants in the HIVNET 006 and 012 cohorts as a consequence of use of an agent with a long t½ as monotherapy in individuals with high viral loads.
- Trial name
- NCT00193947
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- University Health Network, Toronto
HIV Infections
Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune
The question that prompted this study is the extent to which results from clinical trials can be translated into everyday practice (external validity).
- Trial name
- NCT00979420
- Where
- 60 sites in Germany
- Sponsor
- Boehringer Ingelheim
HIV Infections
Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients
This observational study is supposed to assess (under conditions of clinical practice in daily routine) whether treatment with Viramune (nevirapine) in combination with Truvada (tenofovir and emtricitabine) will durably suppress…
- Trial name
- NCT00543803
- Where
- 63 sites in Germany
- Volunteers
- 334 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine
To assess the safety and toxicity of zidovudine (AZT)/didanosine (ddI) versus AZT/ddI combined with nevirapine in HIV-infected patients, and to obtain preliminary anti-HIV activity data using immunologic and virologic markers.
- Trial name
- NCT00000770
- Testing
- Nevirapine, Zidovudine, Didanosine
- Where
- 44 sites in United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)
To determine the relative clinical efficacy of zidovudine ( AZT ) plus didanosine (ddI), AZT plus zalcitabine ( ddC ), AZT alternating monthly with ddI, and AZT/ddI plus nevirapine in HIV-infected patients with advanced disease.
- Trial name
- NCT00000781
- Testing
- Nevirapine, Zidovudine, Zalcitabine
- Where
- 96 sites in United States, Puerto Rico
- Volunteers
- 1,292 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)